Editorial: In vitro mechanistic evaluation of nucleic acid polymers: A cautionary tale
[Display omitted] The LNA-modified NAP ALG-10133 is inactive against HBV infection in humans compared with the potent activity of non-LNA-modified NAPs such as REP 2139. This inactivity illustrates the negative impact LNA has on the antiviral activity of NAPs and highlights critical artifacts in tra...
Saved in:
Published in | Molecular therapy. Nucleic acids Vol. 28; pp. 168 - 174 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
14.06.2022
American Society of Gene & Cell Therapy Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | [Display omitted]
The LNA-modified NAP ALG-10133 is inactive against HBV infection in humans compared with the potent activity of non-LNA-modified NAPs such as REP 2139. This inactivity illustrates the negative impact LNA has on the antiviral activity of NAPs and highlights critical artifacts in transfection-based systems used for their in vitro evaluation. |
---|---|
Bibliography: | SourceType-Other Sources-1 content type line 63 ObjectType-Editorial-2 ObjectType-Commentary-1 |
ISSN: | 2162-2531 2162-2531 |
DOI: | 10.1016/j.omtn.2022.03.002 |